Miles Gerson

Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021.

Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware.

Integra Therapeutics SL is a Spanish Barcelona-based company founded in 2020 by Marc Güell and Avencia Sánchez-Mejías, with Avencia Sánchez-Mejías serving as the CEO since then. The company is focused on engineering the next-generation of gene writing tools to cure genetic and oncological diseases with high unmet medical need. Integra Therapeutics is committed to creating new gene writing tools that improve the scope, efficiency, and safety of advanced therapies.

Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California.